Filing Flows › Prelude Therapeutics (PRLD) › Q1 2026 › vs Q4 2025
Prelude Therapeutics (PRLD) Q1 2026 vs Q4 2025 (quarter over quarter)
Prelude Therapeutics's revenue fell $1.1M (-19%) from $5.6M in Q4 2025 to $4.6M in Q1 2026.
Prelude Therapeutics, Q1 2026: revenue $4.6M, operating margin -309.5%, net loss $10.4M, operating cash flow −$21.7M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $4.6M | $5.6M | −$1.1M | -19% |
| Other income, net | $3.8M | $891K | $2.9M | +326% |
| Net loss | $10.4M | $16.5M | −$6.1M | -37% |
| Costs & expenses | $18.8M | $23.0M | −$4.2M | -18% |
| Operating costs | $18.8M | $23.0M | −$4.2M | -18% |
| Research & development | $13.6M | $18.0M | −$4.4M | -24% |
| General & admin | $5.2M | $5.0M | $160K | +3% |
| Operating cash sources | $24.1M | −$20.9M | $44.9M | — |
| Depreciation & amortization | $391K | $418K | −$27K | -6% |
| Share-based compensation | $2.0M | $1.8M | $156K | +8% |
| Cash used in operations | $21.7M | −$23.1M | $44.8M | — |
| Net loss absorbed | $10.4M | $16.5M | −$6.1M | -37% |
| Working capital & other | $13.7M | −$37.3M | $51.0M | — |
Questions
How much did Prelude Therapeutics's revenue grow quarter over quarter in Q1 2026?
Prelude Therapeutics's revenue fell $1.1M (-19%) from $5.6M in Q4 2025 to $4.6M in Q1 2026.